Ark Therapeutics Group plc – Product Pipeline Review – 2012

Date: May 15, 2012
Pages: 66
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: A61E4D40E2CEN
Leaflet:

Download PDF Leaflet

Ark Therapeutics Group plc - Product Pipeline Review - 2012

Summary

Global Market Direct’s pharmaceuticals report, “Ark Therapeutics Group plc - Product Pipeline Review - 2012” provides data on the Ark Therapeutics Group plc’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Ark Therapeutics Group plc’s corporate website, SEC filings, investor presentations and featured press releases, both from Ark Therapeutics Group plc and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Ark Therapeutics Group plc - Brief Ark Therapeutics Group plc overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Ark Therapeutics Group plc human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Ark Therapeutics Group plc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Ark Therapeutics Group plc’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Ark Therapeutics Group plc’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Ark Therapeutics Group plc in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Ark Therapeutics Group plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Ark Therapeutics Group plc.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Ark Therapeutics Group plc and identify potential opportunities in those areas.

Keyword

Current R&D Portfolio of Ark Therapeutics Group plc; Ark Therapeutics Group plc - Key Therapeutics; Ark Therapeutics Group plc - Pipeline Overview and Promising Molecules; Ark Therapeutics Group plc - News; Ark Therapeutics Group plc - Latest Updates; Ark Therapeutics Group plc - Pipeline; Ark Therapeutics Group plc - Discontinued/Dormant Projects
Ark Therapeutics Group plc Snapshot
Ark Therapeutics Group plc Overview
Key Information
Key Facts
Ark Therapeutics Group plc – Research and Development Overview
Key Therapeutic Areas
Ark Therapeutics Group plc – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Ark Therapeutics Group plc – Pipeline Products Glance
Ark Therapeutics Group plc Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Ark Therapeutics Group plc – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Ark Therapeutics Group plc – Drug Profiles
EG005
  Product Description
  Mechanism of Action
  R&D Progress
EG011
  Product Description
  Mechanism of Action
  R&D Progress
EG01257
  Product Description
  Mechanism of Action
  R&D Progress
EG013
  Product Description
  Mechanism of Action
  R&D Progress
EG014
  Product Description
  Mechanism of Action
  R&D Progress
EG015
  Product Description
  Mechanism of Action
  R&D Progress
EG016
  Product Description
  Mechanism of Action
  R&D Progress
Neuropilin 1 Antagonist Programme
  Product Description
  Mechanism of Action
  R&D Progress
Peptide For Cancer And Eye Disease
  Product Description
  Mechanism of Action
  R&D Progress
Ark Therapeutics Group plc – Pipeline Analysis
Ark Therapeutics Group plc – Pipeline Products by Therapeutic Class
Ark Therapeutics Group plc – Pipeline Products By Target
Ark Therapeutics Group plc – Pipeline Products by Route of Administration
Ark Therapeutics Group plc – Pipeline Products By Mechanism of Action
Ark Therapeutics Group plc – Recent Pipeline Updates
Ark Therapeutics Group plc - Dormant Projects
Ark Therapeutics Group plc – Company Statement
Ark Therapeutics Group plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Ark Therapeutics Group plc, Recent Developments
Ark Therapeutics Group plc- Press Release
Feb 08, 2012: Ark Therapeutics Announces Notice Of Allowance Of US Patent For Neuropilin-1 Receptor Small Molecule Antagonists
Dec 18, 2009: Ark Therapeutics Announces CHMP To Adopt Negative Opinion For Marketing Authorization Application (MAA) Of Cerepro
Sep 04, 2009: Ark Therapeutics Receives Positive Feedback From MHRA Scientific Advice Meeting On EG013 For Foetal Growth Restriction
Aug 26, 2009: Ark's VEGF D Gene-based Medicine To Commence Phase I/IIa Development In Refractory Angina
May 21, 2009: Trinam Phase III Study Enrols First Patient
May 05, 2009: Ark's Trinam Awarded Fast Track Status By FDA
Jan 08, 2009: Ark Completes Potency Test Qualification Enabling Trinam Phase III Trial To Commence
Financial Deals Landscape
Ark Therapeutics Group plc, Deals Summary
Ark Therapeutics Group plc, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Lymphatix Secures $1.18 Million In A Financing Round
Partnerships
Ark Therapeutics Enters Into Licensing Agreement With Sino Tau
Domainex Extends Its Research Agreement With Ark Therapeutics
Ark Therapeutics Signs A Licensing Agreement With Lab21
Ark Therapeutics Signs An Agreement With Flen Pharma
Ark Therapeutics Signs An Agreement With Teva Medical
Licensing Agreements
Ark Therapeutics Extends Licensing Agreement With Crucell
Ark Therapeutics Signs Licencing Agreement With Boehringer Ingelheim
Ark Therapeutics Signs A Licensing Agreement With Oy Lx Therapies
Ark Therapeutics Enters Into License Agreement With Eyecopharm
Equity Offering
Ark Therapeutics Completes Private Placement Of $78 Million
Ark Therapeutics Completes Private Placement Of $12 Million
Ark Therapeutics Completes Private Placement Of $12.20 Million
Ark Therapeutics Completes Public Offering Of $36 Million
Ark Therapeutics Group Completes IPO Of $104 Million
Acquisition
Ark Therapeutics Completes Sale Of Patient Plus To Crawford Healthcare
Ark Therapeutics Acquires Lymphatix
Ark Therapeutics Acquires 9% Interest In Eyecopharm
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Ark Therapeutics Group plc, Key Information
Ark Therapeutics Group plc, Key Facts
Ark Therapeutics Group plc – Pipeline by Indication, 2012
Ark Therapeutics Group plc – Pipeline by Stage of Development, 2012
Ark Therapeutics Group plc – Monotherapy Products in Pipeline, 2012
Ark Therapeutics Group plc – Phase II, 2012
Ark Therapeutics Group plc – Pre-Clinical, 2012
Ark Therapeutics Group plc – Pipeline By Therapeutic Class, 2012
Ark Therapeutics Group plc - Pipeline By Target, 2012
Ark Therapeutics Group plc – Pipeline By Route of Administration, 2012
Ark Therapeutics Group plc – Pipeline Products By Mechanism of Action, 2012
Ark Therapeutics Group plc – Recent Pipeline Updates, 2012
Ark Therapeutics Group plc - Dormant Developmental Projects,2012
Ark Therapeutics Group plc, Subsidiaries
Ark Therapeutics Group plc, Deals Summary
Lymphatix Secures $1.18 Million In A Financing Round
Ark Therapeutics Enters Into Licensing Agreement With Sino Tau
Domainex Extends Its Research Agreement With Ark Therapeutics
Ark Therapeutics Signs A Licensing Agreement With Lab21
Ark Therapeutics Signs An Agreement With Flen Pharma
Ark Therapeutics Signs An Agreement With Teva Medical
Ark Therapeutics Extends Licensing Agreement With Crucell
Ark Therapeutics Signs Licencing Agreement With Boehringer Ingelheim
Ark Therapeutics Signs A Licensing Agreement With Oy Lx Therapies
Ark Therapeutics Enters Into License Agreement With Eyecopharm
Ark Therapeutics Completes Private Placement Of $78 Million
Ark Therapeutics Completes Private Placement Of $12 Million
Ark Therapeutics Completes Private Placement Of $12.20 Million
Ark Therapeutics Completes Public Offering Of $36 Million
Ark Therapeutics Group Completes IPO Of $104 Million
Ark Therapeutics Completes Sale Of Patient Plus To Crawford Healthcare
Ark Therapeutics Acquires Lymphatix
Ark Therapeutics Acquires 9% Interest In Eyecopharm

LIST OF FIGURES

Ark Therapeutics Group plc – Pipeline by Indication, 2012
Ark Therapeutics Group plc – Pipeline by Stage of Development, 2012
Ark Therapeutics Group plc – Monotherapy Products in Pipeline, 2012
Ark Therapeutics Group plc – Pipeline By Therapeutic Class, 2012
Ark Therapeutics Group plc - Pipeline By Target, 2012
Ark Therapeutics Group plc – Pipeline By Route of Administration, 2012

Ask Your Question

Ark Therapeutics Group plc – Product Pipeline Review – 2012
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: